Followers | 35 |
Posts | 7503 |
Boards Moderated | 0 |
Alias Born | 02/15/2012 |
Friday, April 14, 2017 10:40:04 PM
Like any shareholder that large participating in the providing the majority of funding they are protecting themselves and creating discounts and looking to use postential synergies, and asset/ intangibles control....etc.
That's not my point. My point is that there are countless ways for them to do the above. We have none.
If cvm bk. There all multiple entries that get MK for free.
They can say a $50m building is worth $25m and another entity they own could purchase it at discount.
They could intangibles are $5m. And reap profits later via other enitity....and so on.
These are the risks and privileges of being a large funder in across multiple entities in this space.
Let's say the get bought out for 100m. What changed in company in last 6 months? Other than dilution and cvm doing their best to play stupid with the FDA!
Share structure changed quite a bit; thus $100m is divided by 400m vs 100m shares.....25 cents vs $1...
In even the last 3 most critical years, with a massive study in play the final findings are so weak currently that nobody has taken an activist or hostile position.
This implies that nothing significant will come to fruition in near term. (By significant I mean game changing $1+ pps). Personally I was not here for a 300% return if I catch the bottom perfectly.
I also believe that 300% return is available, but with all the ongoing issues, an extension will be created to allow for atleast one more internal recapitalization...if not 2.
300% isn't bad return either, but with all the options available....
Accept the $75m market cap rule keeps me interested.
So, the must produce $75m market cap via common. Or issue preffered soon.
I'm a seller as soon as possible crosses 10% to fully diluted $75m market cap (with my small position)
If they go with preffered units to raise capital i will revisit my position then.
The science itself has zero chance of taking this stock to the moon anytime soon.
Asset management...
$75m market cap
Fully diluted
Preferred units
No hostile positions
Recent CVM News
- CEL-SCI Appoints Mario Gobbo to Its Board of Directors • Business Wire • 04/23/2024 01:00:00 PM
- CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology • Business Wire • 03/19/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 03/07/2024 04:33:42 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 04:33:13 PM
- CEL-SCI Corporation Issues Letter to Shareholders • Business Wire • 03/06/2024 01:45:00 PM
- CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results • Business Wire • 02/15/2024 01:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:31:12 PM
- CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/13/2024 05:00:00 PM
- CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock • Business Wire • 02/09/2024 01:30:00 PM
- CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug • Business Wire • 02/06/2024 02:00:00 PM
- European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine® • Business Wire • 01/31/2024 02:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:06:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:03:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 02:00:11 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/22/2023 09:01:06 PM
- CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments • Business Wire • 12/22/2023 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/21/2023 09:15:39 PM
- UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer • Business Wire • 12/04/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 10:25:18 PM
- CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock • Business Wire • 11/20/2023 09:15:00 PM
- CEL-SCI Announces Pricing of $5 Million Offering of Common Stock • Business Wire • 11/16/2023 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2023 09:01:26 PM
FEATURED Cannabix's Breath Logix Alcohol Device Delivers Positive Impact to Private Monitoring Agency in Montana, USA • Apr 25, 2024 8:52 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM
Kona Gold Beverages, Inc. Announces Name Change to NuVibe, Inc. and Initiation of Ticker Symbol Application Process • KGKG • Apr 25, 2024 8:30 AM
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM